As is known to us all, in the process of gas phase analysis, column is the “heart” of gas chromatograph, and it plays a crucial role in the qualitative and quantitative analysis of components. Recently, followers often consult about the aging of GC column. Today, we would like to share that with you.
Aging of GC column, in short, refers to the process of restoring column efficiency by baking the column at high temperature and taking the unstable stationary phase, possible impurities and pollutants out of the column by carrier gas.
What are the conditions that require aging treatment of the column?
1. Newly purchased column: For new column, prior to its initial use, the aging treatment can remove the stationary liquid that bonded unstably in the column or residual solvent in the packed column to ensure the stability of the properties of the new column.
2. For columns that have been left unused for a long time and need to be started again, the aging of the column can remove pollutants, oxygen and water caused by column being placed for a long time. And restore the properties of the column.
3. Columns that have been used for a long time or that have been through complex matrices and mass sample analysis: in this case, high boiling point impurities and pollutants remaining in the column can be mainly removed by aging; On the other hand, long-term use of column under high temperature will cause the loss of stationary liquid, exposing part of the active site. Through aging treatment, using the characteristics of thermal expansion and cold shrinkage of stationary phase, the active site on the inner wall of the column can be covered again. And restore the properties of the column.
How to operate, and what details do we need to pay attention to during the aging process?
1. Selection of aging temperature
In general, the aging temperature can be controlled between the maximum analytical temperature of the method and the upper limit of the constant temperature of the column.
The aging temperature can also be set to 20-30℃ lower than the upper limit of the column constant temperature; Or 20-30℃ higher than the maximum analysis temperature of the method.
It is important to note that each GC column has a temperature limit to which it can tolerate, and it is necessary to read the column box or instructions carefully before aging. In the aging process, once the column temperature limit is exceeded, it will lead to the loss of stationary phase and shorten the lifetime. Therefore, aging temperature can be lower as far as possible under the premise of ensuring the removal of impurities and pollutants.
2. Aging time
The specific aging process is generally set as program heating (slowly heating up to the set aging temperature), such as: the initial temperature is 35℃, 2-5℃/min, heating up to the aging temperature, and keeping 0.5-2h. The specific aging time can be determined according to the effect of impurity removal.
3. Prevent oxygen into the column
Because at high temperatures, with the presence of oxygen, the stationary liquid is easily oxidized, the stable silane bond will break, causing serious column loss and column efficiency declination.
Therefore, in order to avoid oxygen entering the column, the following points should be noted:
● Connect the gas inlet of the column to the injection port of the instrument. Place the end of the column in alcohol and take carrier gas to observe whether there are continuous bubbles. If not, check the column for mid-section fracture, installation, and leakage of the system.
● Set the carrier gas flow rate to the normal working value, the injection port, column oven and detector (if connected to the detector) to 35℃ or turned off the instrument temperature control system. The carrier gas is available for 15-30 minutes at room temperature to replace the oxygen that may exist in the instrument system and the column.
● Ensure that the other joints of the instrument are properly installed and pass leaking test.
4. Avoid pollution
In general, in order to avoid contamination of the detector, it is not recommended to connect the detector during the aging process. The normal operation is to use a solid pressure ring to plug the lower end of the detector and close the temperature. If the detector is connected, for the FID detector, there is no need to ignite, and air and hydrogen need not be turned on; If it is an ECD detector, tailing blowing should be set to avoid excessive heat and temperature which transfer to the ECD, so as to ensure the safety of the radioactive source inside the detector. In addition, it is prohibited to use hydrogen to age the column, that is to avoid hydrogen leakage and accumulation in the column temperature chamber, which will cause explosion.
5. Relevant maintenance shall be carried out before aging
For columns that have been used for a long time or that have through analysis of complex matrices and multiple samples, aging is to remove some of the residual contaminants. These contaminants tend to be compounds with higher boiling points which accumulate at the head of the column, such as proteins, pigments, gels, etc. in the sample. In order to avoid the pollutants to continue to transfer to the column while they can not be completely removed from the column inside the column, before aging column should be cut, appropriately cut off part of the column. In addition, it is necessary to maintain the injector liner, quartz cotton and the injector spacer to avoid secondary contamination of the column in the aging process. In conclusion, aging of column is meaningful after removing the source of pollution.
Tag :// #GC
1. Instrument
performance
ICP-OES quantitation is based on measurement of excited atoms and ions at the wavelength characteristics for the specific elements being measured. ICP-MS, however, measures an atom’s mass by mass spectrometry (MS). Due to the difference in metal element detection, the lower detection limit for ICP-MS can extend to parts per trillion (ppt), where the lower limit for ICP-OES is parts per billion (ppb). Obviously, if the elements for detection have regulatory limits that are below or near the lower detection limit of ICP-OES, ICP-MS is the instrument of choice.
ICP-OES quantitation is based on measurement of excited atoms and ions at the wavelength characteristics for the specific elements being measured. ICP-MS, however, measures an atom’s mass by mass spectrometry (MS). Due to the difference in metal element detection, the lower detection limit for ICP-MS can extend to parts per trillion (ppt), where the lower limit for ICP-OES is parts per billion (ppb). Obviously, if the elements for detection have regulatory limits that are below or near the lower detection limit of ICP-OES, ICP-MS is the instrument of choice.
2. Characteristics of
the environmental sample
ICP-OES is mainly used for samples with high total dissolved solids (TDS) or suspended solids and is, therefore, more robust for analyzing ground water, wastewater, soil, and solid waste. It can be used for drinking water analysis as well. But in general, ICP-OES is used to measure contaminants for environmental safety assessment and elements with a higher regulatory limit. ICP-MS, on the other hand, is especially useful for analyzing samples with low regulatory limits. In addition, ICP-OES has much higher tolerance for TDS (up to 30%). ICP-MS has much lower tolerance for TDS (about 0.2%) although there are ways to increase the tolerance. Although both ICP-OES and ICP-MS can be used for high matrix samples, sample dilution is often necessary for use on ICP-MS. In addition, if a sample contains analytes of great difference in concentration, ICP-MS has wider dynamic linear range so the sample may not be diluted to detect these elements at the same time.
ICP-OES is mainly used for samples with high total dissolved solids (TDS) or suspended solids and is, therefore, more robust for analyzing ground water, wastewater, soil, and solid waste. It can be used for drinking water analysis as well. But in general, ICP-OES is used to measure contaminants for environmental safety assessment and elements with a higher regulatory limit. ICP-MS, on the other hand, is especially useful for analyzing samples with low regulatory limits. In addition, ICP-OES has much higher tolerance for TDS (up to 30%). ICP-MS has much lower tolerance for TDS (about 0.2%) although there are ways to increase the tolerance. Although both ICP-OES and ICP-MS can be used for high matrix samples, sample dilution is often necessary for use on ICP-MS. In addition, if a sample contains analytes of great difference in concentration, ICP-MS has wider dynamic linear range so the sample may not be diluted to detect these elements at the same time.
3. Regulatory
requirements
In the U.S., the regulatory compliance monitoring for ICP-OES is governed by EPA Methods 200.5 and 200.7. EPA Method 200.7 was approved for use as axial view of ICP-OES and is therefore the EPA method for compliance monitoring by ICP-OES. EPA Method 200.8 governs regulatory compliance using ICP-MS. Both EPA 200.7 and 200.8 can be used for compliance of the Safe Drinking Water Act (SDWA) and the Clean Water Act (CWA).
For drinking water regulatory compliance or SDWA compliance, either ICP-OES or ICP-MS alone is not sufficient. Regulatory compliance can be accomplished by the combination of ICP-OES (for minerals) and ICP-MS, or ICP-OES and GFAA (using EPA 200.9), or ICP-MS and GFAA (for minerals). ICP-OES cannot be used to measure arsenic, mercury, and some other toxic metals with very low regulatory limits using EPA Method 200.7. ICP-MS can’t be used to measure the minerals (Na, K, Ca, Mg, and Fe) in drinking water using EPA Method 200.8. It is also important to mention that current EPA Method 200.8 version 5.4 cannot use collision cell technology for drinking water analysis, reducing the power to use ICP-MS to minimize polyatomic interferences.
In the U.S., the regulatory compliance monitoring for ICP-OES is governed by EPA Methods 200.5 and 200.7. EPA Method 200.7 was approved for use as axial view of ICP-OES and is therefore the EPA method for compliance monitoring by ICP-OES. EPA Method 200.8 governs regulatory compliance using ICP-MS. Both EPA 200.7 and 200.8 can be used for compliance of the Safe Drinking Water Act (SDWA) and the Clean Water Act (CWA).
For drinking water regulatory compliance or SDWA compliance, either ICP-OES or ICP-MS alone is not sufficient. Regulatory compliance can be accomplished by the combination of ICP-OES (for minerals) and ICP-MS, or ICP-OES and GFAA (using EPA 200.9), or ICP-MS and GFAA (for minerals). ICP-OES cannot be used to measure arsenic, mercury, and some other toxic metals with very low regulatory limits using EPA Method 200.7. ICP-MS can’t be used to measure the minerals (Na, K, Ca, Mg, and Fe) in drinking water using EPA Method 200.8. It is also important to mention that current EPA Method 200.8 version 5.4 cannot use collision cell technology for drinking water analysis, reducing the power to use ICP-MS to minimize polyatomic interferences.
Comparison of
ICP-MS and ICP-OES Advantages and Methods
|
|
ICP-MS
Main advantages
ICP-MS is
becoming a workhorse for metal analysis in water not only because it offers
lower detection limit. The following features also contribute its wide range
of environmental applications:
·
Wide dynamic range
·
Efficiently remove polyatomic spectral
interferences using collision cell technology
·
Rapid semi-quantitative analysis
·
Isotopic analysis
Regulatory
methods
·
EPA 200.8
·
EPA 321.8 (IC-ICP-MS)
·
EPA 6020
·
ISO/DIS 17294-1:2004
·
ISO 17294-2:2016
·
NEN 6427:1999
|
ICP-OES
Main advantages
ICP-OES is used
for all the matrices of environmental samples especially for high-matrix
samples. The following features also contribute its wide range of environmental
applications:
·
Only analytical grade reagents are sufficient
·
Simpler method development does not need a
specialist with highly technical expertise
·
Overall is a cheaper option if the elements do
not need lower detection limit that ICP-MS delivers
Regulatory
methods
·
EPA 200.5
·
EPA 200.7
·
EPA 6010
·
ISO 11885:2007
·
ISO/TC 190/SC3/WG1 N0252
·
NPR 6425:1995
·
NEN 6426:1995
·
EN 12506: 2003
|
Yours Chromatographically
Kaushik Zala
Ref., https://www.thermofisher.com/in/en/home/industrial/environmental/environmental-learning-center/contaminant-analysis-information/metal-analysis/comparison-icp-oes-icp-ms-trace-element-analysis.html
Hydrophilic interaction chromatography (or hydrophilic interaction liquid chromatography, HILIC) is a variant of normal phase liquid chromatography that partly overlaps with other chromatographic applications such as ion chromatography and reversed phase liquid chromatography. HILIC uses hydrophilic stationary phases with reversed-phase type eluents. The name was suggested by Dr. Andrew Alpert in his 1990 paper on the subject.[1] He described the chromatographic mechanism for it as liquid-liquid partition chromatography where analytes elute in order of increasing polarity, a conclusion supported by a review and re-evaluation of published data.[2]
More Coming Soon
Yours Charomatographically
Kaushik Zala
Tag :// #HILIC
Batch: A specific quantity of a drug or other material produced according to a single
manufacturing order during the same cycle of manufacture and intended to have uniform character
and quality, within specified limits (21 CFR 210.3(b)(2)).
Batch formula (composition): A complete list of the ingredients and their amounts to be used for the manufacture of a representative batch of the drug product. All ingredients should be included in the batch formula whether or not they remain in the finished product (Guideline for Submitting Documentation for the Manufacture of and Controls for Drug Products, FDA, February 1987).
Bioavailability: The rate and extent to which the active drug ingredient or therapeutic moiety is absorbed from a drug product and becomes available at the site of drug action (21 CFR 320.1(a)).
Biobatch: A lot of drug product formulated for purposes of pharmacokinetic evaluation in a bioavailability/bioequivalency study. This lot should be 10% or greater than the proposed commercial production batch or at least 100,000 units, whichever is greater.
Bioequivalent drug products: Pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of the therapeutic moiety under similar experimental conditions, either single dose or multiple dose. Some pharmaceutical equivalents or pharmaceutical alternatives may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on chronic use, or are considered medically insignificant for the particular drug product studied (21 CFR 320.1(e)).
Convolution: Prediction of plasma drug concentrations using a mathematical model based on the convolution integral. For example, the following convolution integral equation may be used to predict the plasma concentration (c(t)) resulting from the absorption rate time course (r ): abs c(t) = I0 c* (t-u) rabs(u) du t The function c represents the concentration time course that would result from the instantaneous * absorption of a unit amount of drug and can be estimated from either i.v. bolus data, oral solution, suspension or rapidly releasing (in vivo) immediate release dosage forms.
Correlation: As used in this guidance, a relationship between in vitro dissolution rate and in vivo input (absorption) rate.
Deconvolution: Estimation of the time course of drug input (usually in vivo absorption or dissolution) using a mathematical model based on the convolution integral. For example, the 22 absorption rate time course (rabs) that resulted in the plasma concentrations (c(t)) may be estimated by solving the following convolution integral equation for r : abs c(t) = I0 c* (t-u) rabs(u) du t The function c represents the concentration time course that would result from the instantaneous * absorption of a unit amount of drug and is typically estimated from either i.v. bolus data, oral solution, suspension or rapidly releasing (in vivo) immediate release dosage forms.
Development: Establishing an in vitro/in vivo correlation.
Drug product: A finished dosage form, e.g., tablet, capsule, or solution, that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients (21 CFR 314.3(b)).
Extended release dosage form: A dosage form that allows a reduction in dosing frequency as compared to that presented by a conventional dosage form, e.g., a solution or an immediate release dosage form
Evaluation: In the context of in vitro/in vivo correlation, a broad term encompassing experimental and statistical techniques used during development and evaluation of a correlation which aid in determining the predictability of the correlation.
Formulation: A listing of the ingredients and composition of the dosage form.
In vitro/in vivo correlation: A predictive mathematical model describing the relationship between an in vitro property of an extended release dosage form (usually the rate or extent of drug dissolution or release) and a relevant in vivo response, e.g., plasma drug concentration or amount of drug absorbed.
In vivo dissolution: The process of dissolution of drug in the gastro-intestinal tract.
In vitro release: Drug dissolution (release) from a dosage form as measured in an in vitro dissolution apparatus
In vivo release: In vivo dissolution of drug from a dosage form as determined by deconvolution of data obtained from pharmacokinetic studies in humans (patients or healthy volunteers).
Level A correlation: A predictive mathematical model for the relationship between the entire in vitro dissolution/release time course and the entire in vivo response time course, e.g., the time course of plasma drug concentration or amount of drug absorbed.
Level B correlation: A predictive mathematical model for the relationship between summary parameters that characterize the in vitro and in vivo time courses, e.g., models that relate the mean in vitro dissolution time to the mean in vivo dissolution time, the mean in vitro dissolution time to the mean residence time in vivo, or the in vitro dissolution rate constant to the absorption rate constant.
Level C correlation: A predictive mathematical model of the relationship between the amount dissolved in vitro at a particular time (or the time required for in vitro dissolution of a fixed percent of the dose, e.g., T50%) and a summary parameter that characterizes the in vivo time course (e.g., Cmax or AUC)
Lot: A batch, or a specific identified portion of a batch, having uniform character and quality within specified limits or, in the case of a drug product produced by continuous process, a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits (21 CFR 210.3(b)(10)).
Mean absorption time: The mean time required for drug to reach systemic circulation from the time of drug administration. This term commonly refers to the mean time involved in the in vivo release and absorption processes as they occur in the input compartment and is estimated as MAT = MRToral - MRTi.v
Mean in vivo dissolution time: For a solid dosage form: MDT = MRT - MRT . This solid solid solution reflects the mean time for drug to dissolve in vivo.
Mean residence time: The mean time that the drug resides in the body. MRT may also be the mean transit time. MRT = AUMC/AUC.
Narrow therapeutic index drugs: Drugs having, for example, less than a two-fold difference in the minimum toxic concentrations and the minimum effective concentrations (21 CFR 320.33 (c)).
Nonrelease controlling excipient (noncritical compositional variable): An inactive ingredient in the final dosage form that does not significantly affect the release of the active drug substance from the dosage form.
Predictability: Verification of the model's ability to describe in vivo bioavailability results from a test set of in vitro data (external predictability) as well as from the data that was used to develop the correlation (internal predictability)
Percent prediction error: % PE = [(Observed value - Predicted value) / Observed value] x 100
Release controlling excipient (critical compositional variable): An inactive ingredient in the final dosage form that functions primarily to extend the release of the active drug substance from the dosage form.
Release mechanism: The process by which the drug substance is released from the dosage form.
Release rate: Amount of drug released per unit of time as defined by in vitro or in vivo testing.
Statistical moments: Parameters that describe the characteristics of the time courses of plasma concentration (area, mean residence time, and variance of mean residence time) and of urinary excretion rate.
Batch formula (composition): A complete list of the ingredients and their amounts to be used for the manufacture of a representative batch of the drug product. All ingredients should be included in the batch formula whether or not they remain in the finished product (Guideline for Submitting Documentation for the Manufacture of and Controls for Drug Products, FDA, February 1987).
Bioavailability: The rate and extent to which the active drug ingredient or therapeutic moiety is absorbed from a drug product and becomes available at the site of drug action (21 CFR 320.1(a)).
Biobatch: A lot of drug product formulated for purposes of pharmacokinetic evaluation in a bioavailability/bioequivalency study. This lot should be 10% or greater than the proposed commercial production batch or at least 100,000 units, whichever is greater.
Bioequivalent drug products: Pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of the therapeutic moiety under similar experimental conditions, either single dose or multiple dose. Some pharmaceutical equivalents or pharmaceutical alternatives may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on chronic use, or are considered medically insignificant for the particular drug product studied (21 CFR 320.1(e)).
Convolution: Prediction of plasma drug concentrations using a mathematical model based on the convolution integral. For example, the following convolution integral equation may be used to predict the plasma concentration (c(t)) resulting from the absorption rate time course (r ): abs c(t) = I0 c* (t-u) rabs(u) du t The function c represents the concentration time course that would result from the instantaneous * absorption of a unit amount of drug and can be estimated from either i.v. bolus data, oral solution, suspension or rapidly releasing (in vivo) immediate release dosage forms.
Correlation: As used in this guidance, a relationship between in vitro dissolution rate and in vivo input (absorption) rate.
Deconvolution: Estimation of the time course of drug input (usually in vivo absorption or dissolution) using a mathematical model based on the convolution integral. For example, the 22 absorption rate time course (rabs) that resulted in the plasma concentrations (c(t)) may be estimated by solving the following convolution integral equation for r : abs c(t) = I0 c* (t-u) rabs(u) du t The function c represents the concentration time course that would result from the instantaneous * absorption of a unit amount of drug and is typically estimated from either i.v. bolus data, oral solution, suspension or rapidly releasing (in vivo) immediate release dosage forms.
Development: Establishing an in vitro/in vivo correlation.
Drug product: A finished dosage form, e.g., tablet, capsule, or solution, that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients (21 CFR 314.3(b)).
Extended release dosage form: A dosage form that allows a reduction in dosing frequency as compared to that presented by a conventional dosage form, e.g., a solution or an immediate release dosage form
Evaluation: In the context of in vitro/in vivo correlation, a broad term encompassing experimental and statistical techniques used during development and evaluation of a correlation which aid in determining the predictability of the correlation.
Formulation: A listing of the ingredients and composition of the dosage form.
In vitro/in vivo correlation: A predictive mathematical model describing the relationship between an in vitro property of an extended release dosage form (usually the rate or extent of drug dissolution or release) and a relevant in vivo response, e.g., plasma drug concentration or amount of drug absorbed.
In vivo dissolution: The process of dissolution of drug in the gastro-intestinal tract.
In vitro release: Drug dissolution (release) from a dosage form as measured in an in vitro dissolution apparatus
In vivo release: In vivo dissolution of drug from a dosage form as determined by deconvolution of data obtained from pharmacokinetic studies in humans (patients or healthy volunteers).
Level A correlation: A predictive mathematical model for the relationship between the entire in vitro dissolution/release time course and the entire in vivo response time course, e.g., the time course of plasma drug concentration or amount of drug absorbed.
Level B correlation: A predictive mathematical model for the relationship between summary parameters that characterize the in vitro and in vivo time courses, e.g., models that relate the mean in vitro dissolution time to the mean in vivo dissolution time, the mean in vitro dissolution time to the mean residence time in vivo, or the in vitro dissolution rate constant to the absorption rate constant.
Level C correlation: A predictive mathematical model of the relationship between the amount dissolved in vitro at a particular time (or the time required for in vitro dissolution of a fixed percent of the dose, e.g., T50%) and a summary parameter that characterizes the in vivo time course (e.g., Cmax or AUC)
Lot: A batch, or a specific identified portion of a batch, having uniform character and quality within specified limits or, in the case of a drug product produced by continuous process, a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits (21 CFR 210.3(b)(10)).
Mean absorption time: The mean time required for drug to reach systemic circulation from the time of drug administration. This term commonly refers to the mean time involved in the in vivo release and absorption processes as they occur in the input compartment and is estimated as MAT = MRToral - MRTi.v
Mean in vivo dissolution time: For a solid dosage form: MDT = MRT - MRT . This solid solid solution reflects the mean time for drug to dissolve in vivo.
Mean residence time: The mean time that the drug resides in the body. MRT may also be the mean transit time. MRT = AUMC/AUC.
Narrow therapeutic index drugs: Drugs having, for example, less than a two-fold difference in the minimum toxic concentrations and the minimum effective concentrations (21 CFR 320.33 (c)).
Nonrelease controlling excipient (noncritical compositional variable): An inactive ingredient in the final dosage form that does not significantly affect the release of the active drug substance from the dosage form.
Predictability: Verification of the model's ability to describe in vivo bioavailability results from a test set of in vitro data (external predictability) as well as from the data that was used to develop the correlation (internal predictability)
Percent prediction error: % PE = [(Observed value - Predicted value) / Observed value] x 100
Release controlling excipient (critical compositional variable): An inactive ingredient in the final dosage form that functions primarily to extend the release of the active drug substance from the dosage form.
Release mechanism: The process by which the drug substance is released from the dosage form.
Release rate: Amount of drug released per unit of time as defined by in vitro or in vivo testing.
Statistical moments: Parameters that describe the characteristics of the time courses of plasma concentration (area, mean residence time, and variance of mean residence time) and of urinary excretion rate.
Extended Release Oral Dosage Forms - Development And Evaluation - Chapter 1_Definitions
Posted by kaushik zala